India's Dr. Reddy's Laboratories is the latest drugmaker to stop distribution of ranitidine, the generic version of Zantac, after a potential cancer-causing impurity was found in the drug, according to Bloomberg.
Dr. Reddy's Laboratories stopped worldwide shipments of the heartburn drug ranitidine after the FDA found it contained N-nitrosodimethylamine, which is classified as a probable human carcinogen.
The Italian Drug Agency and Germany's drug regulator will both order a recall of all versions of Zantac with an active ingredient made in India's Saraca Laboratories, according to Bloomberg. Canada has also asked all makers of ranitidine-containing products to stop distribution.
Last week, Sandoz, the generic arm of Novartis, stopped worldwide distribution of its generic version of Zantac.
Sanofi, the maker of the brand-name Zantac medication, has not halted distribution of any ranitidine products outside of Canada.
Read the full report here.
More articles on pharmacy:
FDA approves first oral treatment for Type 2 diabetes
FDA finalizes rules to prevent improper petitions from delaying drug approvals
Pharmacists can play key role in preventing Hepatitis A outbreak
More articles on pharmacy:
FDA approves first oral treatment for Type 2 diabetes
FDA finalizes rules to prevent improper petitions from delaying drug approvals
Pharmacists can play key role in preventing Hepatitis A outbreak